Generalizability of sodium-glucose co-transporter-2 inhibitors cardiovascular outcome trials to the type 2 diabetes population: a systematic review and meta-analysis

Cardiovascular Diabetology
Marco CastellanaGianluigi Giannelli

Abstract

Cardiovascular outcome trials of sodium-glucose co-transporter-2 inhibitors (SGLT2i CVOTs) found the agents to be associated with clinical benefits in terms of cardiovascular and renal outcomes. We performed a meta-analysis to assess and compare the overall prevalence of eligibility for the enrollment criteria of CANVAS, DECLARE-TIMI 58, EMPA-REG OUTCOME, and VERTIS-CV among unselected patients with type 2 diabetes. This meta-analysis was registered in PROSPERO (CRD42020172032). PubMed, CENTRAL, Scopus and Web of Science were researched in March 2020. Studies evaluating the prevalence of eligibility for each SGLT2i CVOT were selected. Endpoints were estimated using a random-effects model. Five studies, evaluating 1,703,519 patients with type 2 diabetes, were included. Overall, the prevalence of eligible patients according to the enrollment criteria of CANVAS, DECLARE-TIMI 58, EMPA-REG OUTCOME, and VERTIS-CV was 36.4%, 49.5%, 17.0% and 19.0%, respectively. In head-to-head comparisons, DECLARE-TIMI 58 was associated with the highest odds of eligibility (1.74 versus CANVAS, 5.15 versus EMPA-REG OUTCOME and 4.81 versus VERTIS-CV), followed by CANVAS and EMPA-REG OUTCOME/VERTIS-CV. A high heterogeneity was found for all the outcomes...Continue Reading

References

Feb 8, 2008·The New England Journal of Medicine·Peter GaedeOluf Pedersen
Sep 18, 2015·The New England Journal of Medicine·Bernard ZinmanUNKNOWN EMPA-REG OUTCOME Investigators
Feb 21, 2016·Cardiovascular Diabetology·Christian SonessonIngrid Gause-Nilsson
Jun 13, 2017·The New England Journal of Medicine·Bruce NealUNKNOWN CANVAS Program Collaborative Group
Oct 6, 2018·American Heart Journal·Christopher P CannonUNKNOWN VERTIS-CV Investigators
Oct 26, 2018·Advances in Therapy·Lawrence BlondeNeil S Skolnik
Nov 13, 2018·The New England Journal of Medicine·Stephen D WiviottUNKNOWN DECLARE–TIMI 58 Investigators
Jan 12, 2019·Diabetologia·Stuart J McGurnaghanUNKNOWN Scottish Diabetes Research Network Epidemiology Group
Jun 19, 2019·BMC Endocrine Disorders·Guntram SchernthanerHarald Sourij
Jul 25, 2019·Cardiovascular Diabetology·Dario Giugliano, Katherine Esposito
Aug 7, 2019·Cardiovascular Diabetology·Aaron Y KlugerPeter A McCullough
Sep 10, 2019·European Heart Journal·Francesco CosentinoUNKNOWN ESC Scientific Document Group
Dec 22, 2019·Diabetes Care·UNKNOWN American Diabetes Association
Dec 22, 2019·Diabetes Care·UNKNOWN American Diabetes Association

❮ Previous
Next ❯

Citations

Sep 5, 2020·Journal of Diabetes·Theocharis KoufakisKalliopi Kotsa
Mar 27, 2021·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Giuseppina RussoAldo P Maggioni
May 12, 2021·Cardiovascular Diabetology·V SciannameoUNKNOWN DARWIN-T2D Network
Aug 15, 2021·Journal of Diabetes and Its Complications·Johan SundströmUNKNOWN SMARTEST study group (see list in Appendix)
Sep 10, 2021·Cardiovascular Diabetology·Lisanne C A SmidtUNKNOWN UCC-SMART Study Group
Jan 16, 2022·Journal of General Internal Medicine·Alexander ChaitoffMichael A Fischer

❮ Previous
Next ❯

Software Mentioned

CV
EMPA
VERTIS
CANVAS
RevMan5
Science
Scopus
REG
Web
CENTRAL

Related Concepts

Related Feeds

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.